Betahistine is a histamine analogue and a potent H1 receptor agonist with weak H3 receptor antagonist activity. It is primarily used for the symptomatic management of vertigo and Meniere's disease. In the Indian context, it is a first-line prophylactic and therapeutic agent for vestibular disorders, widely prescribed by ENT specialists and neurologists.
Adult: For Meniere's syndrome/Vertigo: Initially, 8 mg orally three times daily (24 mg/day). Maintenance: 24 mg to 48 mg per day in divided doses (e.g., 16 mg three times daily). The dose should be individualized.
Note: Administer with or without food. Tablets should be swallowed whole with a glass of water. For best results, take at regular intervals. Therapy is usually long-term for Meniere's disease.
Betahistine exerts its therapeutic effect primarily by improving microcirculation in the inner ear (cochlear blood flow) and by modulating neuronal activity in the vestibular nuclei. It acts as a partial agonist at postsynaptic histamine H1 receptors in the inner ear, leading to vasodilation of the precapillary sphincters in the stria vascularis. Concurrently, its antagonistic action at presynaptic histamine H3 autoreceptors increases the release of histamine from histaminergic neurons, further potentiating H1-mediated vasodilation and exerting a central inhibitory effect on vestibular nuclei activity.
Pregnancy: Category B: Animal reproduction studies have not shown a risk, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed and potential benefit justifies potential risk to the fetus.
Driving: Betahistine may cause dizziness, drowsiness, or blurred vision in some individuals. Patients should be cautioned about operating machinery or driving until they are certain they are not affected.
| Antihistamines (e.g., Cetirizine, Loratadine, Diphenhydramine) | May antagonize the therapeutic effect of betahistine at H1 receptors, reducing efficacy. | Major |
| Monoamine Oxidase Inhibitors (MAOIs) e.g., Phenelzine, Selegiline | May potentiate the effects of betahistine by inhibiting its metabolism, increasing risk of adverse effects like headache and hypertension. | Major |
| Antihypertensives | Betahistine may cause vasodilation and potentiate the blood pressure-lowering effect, leading to hypotension. | Moderate |
| Sympathomimetics (e.g., Pseudoephedrine) | Additive vasoconstrictive effects may theoretically counteract betahistine's action; clinical significance unclear. | Moderate |